12:30 AM EDT, 09/18/2026 (MT Newswires) -- The European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval for an expanded label for Oncopeptides' Pepaxti (ONCO.ST) as a third-line treatment for multiple myeloma. The Swedish biotech company said Thursday that moving Pepaxti to third-line treatment, up from fourth-line, means patients no longer need to have failed three other drug classes before qualifying. The panel recommended widening approval for Pepaxti, combined with dexamethasone, to treat adult multiple myeloma patients who have already had at least two prior treatments and whose disease no longer responds to lenalidomide or to their most recent therapy.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.